CHRS - Coherus Biosciences: Dumping One Drug But Showing Promise With Another
2024-03-20 20:14:44 ET
Summary
- CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY.
- CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall response rate of 38%.
- Numbers on market share point to a strong Q1'24 for Udenyca, which could increase the market's confidence that CHRS can offset lost revenues from the Cimerli sale.
- CHRS has data in H1'24 from a phase 1 trial of its anti-CCR8 antibody, CHS-114, in solid tumors, adding a catalyst to the calendar.
...
Coherus Biosciences: Dumping One Drug But Showing Promise With Another